Published in J Biol Chem on July 17, 2006
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature (2017) 2.70
α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem (2012) 2.31
100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15
The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A (2008) 2.00
Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem (2008) 1.94
Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med (2008) 1.90
Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol (2008) 1.87
Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc Natl Acad Sci U S A (2011) 1.85
alpha-Synuclein and neuronal cell death. Mol Neurodegener (2009) 1.85
A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci (2010) 1.80
Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci U S A (2009) 1.78
Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One (2010) 1.72
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol (2015) 1.66
Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord (2014) 1.63
Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain (2009) 1.62
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain (2008) 1.61
Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem (2009) 1.57
Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem (2008) 1.54
Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry (2008) 1.50
α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci (2010) 1.49
Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. Mol Cell Proteomics (2008) 1.46
Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci (2010) 1.46
Impact of N-terminal acetylation of α-synuclein on its random coil and lipid binding properties. Biochemistry (2012) 1.44
Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res (2008) 1.40
Transmission of α-synucleinopathy from olfactory structures deep into the temporal lobe. Mol Neurodegener (2016) 1.40
Formation and development of Lewy pathology: a critical update. J Neurol (2009) 1.37
The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease. PLoS Biol (2017) 1.37
Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci (2011) 1.35
Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest (2009) 1.35
Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells. J Neuropathol Exp Neurol (2008) 1.26
Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med (2008) 1.25
Improved immunodetection of endogenous α-synuclein. PLoS One (2011) 1.25
Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A (2013) 1.24
Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm (Vienna) (2010) 1.22
A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation. J Neurochem (2010) 1.22
Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). PLoS One (2011) 1.21
Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum Mol Genet (2009) 1.21
N-Terminal acetylation is critical for forming α-helical oligomer of α-synuclein. Protein Sci (2012) 1.16
Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol (2009) 1.15
Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15
Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol (2012) 1.14
Characterization of semisynthetic and naturally Nα-acetylated α-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of α-synuclein. J Biol Chem (2012) 1.13
α-Synuclein fate is determined by USP9X-regulated monoubiquitination. Proc Natl Acad Sci U S A (2011) 1.13
Proteomic identification of novel proteins associated with Lewy bodies. Front Biosci (2008) 1.13
Small changes huge impact: the role of protein posttranslational modifications in cellular homeostasis and disease. J Amino Acids (2011) 1.12
Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem (2010) 1.11
Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep (2015) 1.10
Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs). Chem Rev (2014) 1.10
Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities. J Neurosci (2012) 1.10
Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther (2014) 1.09
p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol (2007) 1.08
Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. Am J Pathol (2007) 1.08
Synthetic polyubiquitinated α-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. Proc Natl Acad Sci U S A (2013) 1.07
Disruption of protein quality control in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.07
Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J Biol Chem (2010) 1.07
Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts. Acta Neuropathol (2011) 1.06
Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: α-synuclein phosphorylation at tyrosine 125. J Am Chem Soc (2012) 1.06
Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem (2009) 1.05
Inflammation and α-synuclein's prion-like behavior in Parkinson's disease--is there a link? Mol Neurobiol (2012) 1.04
Infectious agents and neurodegeneration. Mol Neurobiol (2012) 1.03
Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease. Anal Chem (2009) 1.03
Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. Front Mol Neurosci (2014) 1.03
A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. Biochim Biophys Acta (2009) 1.02
Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J Neuropathol Exp Neurol (2008) 1.01
Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol (2012) 1.01
Conformational templating of α-synuclein aggregates in neuronal-glial cultures. Mol Neurodegener (2013) 1.01
α-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers. Biochemistry (2013) 1.01
N-terminal acetylation of α-synuclein induces increased transient helical propensity and decreased aggregation rates in the intrinsically disordered monomer. Protein Sci (2012) 1.01
Characterization of kinases involved in the phosphorylation of aggregated α-synuclein. J Neurosci Res (2010) 1.00
rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Mol Neurodegener (2013) 1.00
Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol (2014) 0.99
A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease. Sci Rep (2013) 0.97
Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Curr Neuropharmacol (2013) 0.97
Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. Neurochem Res (2011) 0.97
α-synuclein, LRRK2 and their interplay in Parkinson's disease. Future Neurol (2012) 0.97
N-terminal acetylation stabilizes N-terminal helicity in lipid- and micelle-bound α-synuclein and increases its affinity for physiological membranes. J Biol Chem (2013) 0.97
Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. PLoS Genet (2014) 0.96
Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry. Sci Rep (2014) 0.95
Semisynthetic, site-specific ubiquitin modification of α-synuclein reveals differential effects on aggregation. J Am Chem Soc (2012) 0.95
Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy. PLoS One (2009) 0.95
Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model. Mol Neurodegener (2010) 0.95
The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. Hum Mol Genet (2014) 0.95
Loss of amino-terminal acetylation suppresses a prion phenotype by modulating global protein folding. Nat Commun (2014) 0.95
Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Parkinsons Dis (2011) 0.95
Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion (2009) 0.94
Interaction of α-synuclein with vesicles that mimic mitochondrial membranes. Biochim Biophys Acta (2011) 0.93
Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological α-synuclein by enhanced ELISA. Acta Neuropathol Commun (2014) 0.93
Molecular pathology of Lewy body diseases. Int J Mol Sci (2009) 0.93
Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis (2015) 0.93
Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol Cell Proteomics (2013) 0.92
Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol Dis (2011) 0.92
Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein. Am J Pathol (2013) 0.92
Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. PLoS One (2014) 0.92
Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol (2015) 0.92
Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes. J Biol Chem (2011) 0.91
Regulators and effectors of Siah ubiquitin ligases. Cell Biochem Biophys (2013) 0.91
A cellular model to monitor proteasome dysfunction by alpha-synuclein. Biochemistry (2009) 0.91
α-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2. Proc Natl Acad Sci U S A (2012) 0.91
α-Synuclein and mitochondrial dysfunction in Parkinson's disease. Mol Neurobiol (2013) 0.91
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol (2002) 3.62
Dopamine covalently modifies and functionally inactivates parkin. Nat Med (2005) 3.43
Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron (2005) 3.20
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol (2011) 3.12
Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A (2007) 3.03
Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J (2006) 2.96
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Development and mapping of SSR markers for maize. Plant Mol Biol (2002) 2.83
Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol (2006) 2.59
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A (2003) 2.58
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology (2013) 2.47
Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci (2002) 2.44
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med (2008) 2.37
Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci (2002) 2.35
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun (2006) 2.27
Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol (2006) 2.25
Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem (2007) 2.22
Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One (2011) 2.19
US Features of thyroid malignancy: pearls and pitfalls. Radiographics (2007) 2.18
GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A (2008) 2.17
Integrative analysis of RUNX1 downstream pathways and target genes. BMC Genomics (2008) 2.14
Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science (2009) 2.13
Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol (2011) 2.11
Reconstitution of ThiC in thiamine pyrimidine biosynthesis expands the radical SAM superfamily. Nat Chem Biol (2008) 1.96
CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci U S A (2011) 1.90
Genetic dissection of intermated recombinant inbred lines using a new genetic map of maize. Genetics (2006) 1.89
Diphthamide biosynthesis requires an organic radical generated by an iron-sulphur enzyme. Nature (2010) 1.85
Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci (2005) 1.85
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis (2006) 1.82
Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis. Arch Gen Psychiatry (2006) 1.78
Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis (2008) 1.77
Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci (2007) 1.75
A multicenter randomized comparison of the Endocapsule and the Pillcam SB. Gastrointest Endosc (2008) 1.74
Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol (2008) 1.72
Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci (2008) 1.70
Performance of plate-based cytokine flow cytometry with automated data analysis. BMC Immunol (2003) 1.66
Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain (2009) 1.62
Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol (2005) 1.60
Heterogeneous preferences, decision-making capacity, and phase transitions in a complex adaptive system. Proc Natl Acad Sci U S A (2009) 1.59
Contralateral effects of unilateral strength training: evidence and possible mechanisms. J Appl Physiol (1985) (2006) 1.58
The genetics of Parkinson disease: Implications for neurological care. Nat Clin Pract Neurol (2006) 1.57
Adjacent level ossification development after anterior cervical fusion without plate fixation. Spine (Phila Pa 1976) (2009) 1.55
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem (2008) 1.54
Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement (2013) 1.51
Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol (2005) 1.51
Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology (2007) 1.48
Drosophila neuromuscular synapse assembly and function require the TGF-beta type I receptor saxophone and the transcription factor Mad. J Neurobiol (2003) 1.47
Integrating clinical practice and public health surveillance using electronic medical record systems. Am J Prev Med (2012) 1.46
Anatomic considerations for the placement of C2 laminar screws. Spine (Phila Pa 1976) (2006) 1.46
Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci (2010) 1.46
Editorial comment to standard and saturation transrectal prostate biopsy techniques are equally accurate among prostate cancer active surveillance candidates. Int J Urol (2013) 1.41
Oral cancer campaign. J Am Dent Assoc (2002) 1.39
Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis (2008) 1.39
Penetration of Günther Tulip filter struts through an introducer sheath: case report and safety concerns. J Vasc Interv Radiol (2009) 1.38
Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. Proc Natl Acad Sci U S A (2003) 1.37
Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm (Vienna) (2011) 1.35
Animal models of PD: pieces of the same puzzle? Neuron (2002) 1.34
Mice as models: transgenic approaches and Alzheimer's disease. J Alzheimers Dis (2006) 1.32
Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol Dis (2008) 1.29
Returning to learning following a concussion. Pediatrics (2013) 1.28
Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med (2010) 1.27
Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology (2013) 1.26
Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci (2009) 1.24
Relief as a reward: hedonic and neural responses to safety from pain. PLoS One (2011) 1.24
A GeneTrek analysis of the maize genome. Proc Natl Acad Sci U S A (2007) 1.23
Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum Mol Genet (2009) 1.21
Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. Proc Natl Acad Sci U S A (2004) 1.20
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett (2012) 1.19
Current progress in beta-amyloid immunotherapy. Curr Opin Immunol (2004) 1.18